Venus Remedies Launches Elores Antibiotic in Ecuador to Tackle Rising Antibiotic Resistance

This launch is an extension to the company's ongoing multidrug-resistant infections initiatives in countries such as Saudi Arabia, Myanmar, Oman, Tanzania, Ethiopia, and India.

Haryana-based Venus Remedies Ltd, a pharmaceutical company specialising in oncology treatments, has launched Elores, a novel antibiotic formulation, in Ecuador, South America. 

This launch is an extension to the company's ongoing multidrug-resistant infections initiatives in countries such as Saudi Arabia, Myanmar, Oman, Tanzania, Ethiopia, and India.

Commenting on the launch, Aditi K Chaudhary, president of international business at Venus Remedies, said, "We are thrilled to introduce Elores to the people of Ecuador. With Elores, we aim to provide a reliable and effective solution to healthcare professionals in Ecuador, enabling them to serve their patients better."

Elores, a novel antibiotic formulation, effectively combats multi-drug-resistant infections, enriching Venus Remedies Limited's diverse product portfolio. It combines a beta-lactam antibiotic, a beta-lactamase inhibitor, and an Antibiotic Resistance Breaker (ARB), working synergistically to enhance antibiotic activity and suppress resistance development. 

This approach offers a viable solution against a broad spectrum of bacteria, contributing to improved infection treatment and elevated healthcare standards in Ecuador. 

This dire situation is reflective of a broader challenge faced across Latin America, emphasising the urgent need to address the growth of such pathogens and the resulting surge in infectious diseases.

Based on market analysis, Ecuador's pharmaceutical market was valued at US$1.6 billion in 2020, with India being a significant supplier, providing antibiotics worth US$3.5 million. Venus Remedies Limited's strategic introduction of Elores aligns with the critical need to combat AMR and bolster Ecuador's healthcare system.

Established in 1989 in Haryana, Venus Remedies Limited is a research and development-driven global pharmaceutical company operating in 70 countries. The company boasts a portfolio of research products, both commercialised and in the pipeline, holding more than 500 Marketing Authorizations from regulated and emerging markets.

In a significant development back in September, Venus Remedies expanded its oncology portfolio in South Eastern Europe, securing 511 marketing approvals for its oncology products across 66 countries, reaffirming its commitment to enhancing global healthcare.

The country is currently grappling with alarmingly high rates of antimicrobial resistance (AMR), particularly affecting lethal pathogens, with rates reaching up to 84%.